Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
XNPT's Cash to Debt is ranked higher than
80% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. XNPT: No Debt )
XNPT' s 10-Year Cash to Debt Range
Min: 8.78   Max: No Debt
Current: No Debt

Equity to Asset 0.74
XNPT's Equity to Asset is ranked higher than
77% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. XNPT: 0.74 )
XNPT' s 10-Year Equity to Asset Range
Min: -1.61   Max: 0.82
Current: 0.74

-1.61
0.82
F-Score: 4
Z-Score: 1.77
M-Score: 0.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -104.76
XNPT's Operating margin (%) is ranked higher than
70% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. XNPT: -104.76 )
XNPT' s 10-Year Operating margin (%) Range
Min: -5504.8   Max: 18.25
Current: -104.76

-5504.8
18.25
Net-margin (%) -105.26
XNPT's Net-margin (%) is ranked higher than
70% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. XNPT: -105.26 )
XNPT' s 10-Year Net-margin (%) Range
Min: -4876   Max: 24.77
Current: -105.26

-4876
24.77
ROE (%) -53.76
XNPT's ROE (%) is ranked higher than
64% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. XNPT: -53.76 )
XNPT' s 10-Year ROE (%) Range
Min: -93.4   Max: 27
Current: -53.76

-93.4
27
ROA (%) -39.52
XNPT's ROA (%) is ranked higher than
65% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. XNPT: -39.52 )
XNPT' s 10-Year ROA (%) Range
Min: -127.82   Max: 18.7
Current: -39.52

-127.82
18.7
ROC (Joel Greenblatt) (%) -2033.42
XNPT's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. XNPT: -2033.42 )
XNPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2677.97   Max: 402.46
Current: -2033.42

-2677.97
402.46
Revenue Growth (3Y)(%) -14.50
XNPT's Revenue Growth (3Y)(%) is ranked higher than
68% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. XNPT: -14.50 )
XNPT' s 10-Year Revenue Growth (3Y)(%) Range
Min: -72.6   Max: 126.3
Current: -14.5

-72.6
126.3
EBITDA Growth (3Y)(%) -2.40
XNPT's EBITDA Growth (3Y)(%) is ranked higher than
76% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. XNPT: -2.40 )
XNPT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -54.3   Max: -2.4
Current: -2.4

-54.3
-2.4
EPS Growth (3Y)(%) -4.80
XNPT's EPS Growth (3Y)(%) is ranked higher than
77% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. XNPT: -4.80 )
XNPT' s 10-Year EPS Growth (3Y)(%) Range
Min: -52.3   Max: -4.8
Current: -4.8

-52.3
-4.8
» XNPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

XNPT Guru Trades in Q1 2014

Steven Cohen 16,300 sh (New)
Paul Tudor Jones 41,668 sh (New)
PRIMECAP Management 128,000 sh (unchged)
Jim Simons Sold Out
» More
Q2 2014

XNPT Guru Trades in Q2 2014

John Burbank 17,817 sh (New)
Paul Tudor Jones Sold Out
PRIMECAP Management 104,000 sh (-18.75%)
» More
Q3 2014

XNPT Guru Trades in Q3 2014

John Burbank Sold Out
PRIMECAP Management 91,000 sh (-12.50%)
» More
Q4 2014

XNPT Guru Trades in Q4 2014

Paul Tudor Jones 18,549 sh (New)
Charles Brandes 19,700 sh (New)
PRIMECAP Management 91,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with XNPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.10
XNPT's P/B is ranked higher than
69% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. XNPT: 5.10 )
XNPT' s 10-Year P/B Range
Min: 1.71   Max: 13.19
Current: 5.1

1.71
13.19
P/S 9.56
XNPT's P/S is ranked higher than
74% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. XNPT: 9.56 )
XNPT' s 10-Year P/S Range
Min: 2.65   Max: 111.17
Current: 9.56

2.65
111.17
Current Ratio 6.16
XNPT's Current Ratio is ranked higher than
79% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. XNPT: 6.16 )
XNPT' s 10-Year Current Ratio Range
Min: 3.41   Max: 11.26
Current: 6.16

3.41
11.26
Quick Ratio 6.08
XNPT's Quick Ratio is ranked higher than
79% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. XNPT: 6.08 )
XNPT' s 10-Year Quick Ratio Range
Min: 3.41   Max: 11.26
Current: 6.08

3.41
11.26
Days Inventory 229.95
XNPT's Days Inventory is ranked higher than
81% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. XNPT: 229.95 )
XNPT' s 10-Year Days Inventory Range
Min: 196.85   Max: 237.06
Current: 229.95

196.85
237.06
Days Sales Outstanding 22.55
XNPT's Days Sales Outstanding is ranked higher than
94% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. XNPT: 22.55 )
XNPT' s 10-Year Days Sales Outstanding Range
Min: 4.22   Max: 96.22
Current: 22.55

4.22
96.22

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.50
XNPT's Price/Net Cash is ranked higher than
85% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 103.40 vs. XNPT: 6.50 )
XNPT' s 10-Year Price/Net Cash Range
Min: 2.06   Max: 12.42
Current: 6.5

2.06
12.42
Price/Net Current Asset Value 6.30
XNPT's Price/Net Current Asset Value is ranked higher than
84% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 42.30 vs. XNPT: 6.30 )
XNPT' s 10-Year Price/Net Current Asset Value Range
Min: 1.97   Max: 11.99
Current: 6.3

1.97
11.99
Price/Tangible Book 5.00
XNPT's Price/Tangible Book is ranked higher than
76% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. XNPT: 5.00 )
XNPT' s 10-Year Price/Tangible Book Range
Min: 1.8   Max: 12.9
Current: 5

1.8
12.9
Price/Median PS Value 0.70
XNPT's Price/Median PS Value is ranked higher than
95% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. XNPT: 0.70 )
XNPT' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 6.41
Current: 0.7

0.21
6.41
Earnings Yield (Greenblatt) -14.00
XNPT's Earnings Yield (Greenblatt) is ranked lower than
51% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. XNPT: -14.00 )
XNPT' s 10-Year Earnings Yield (Greenblatt) Range
Min: -14   Max: 4492.4
Current: -14

-14
4492.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:LMW.Germany,
XenoPort Inc is a Delaware corporation was incorporated on May 19, 1999. The Company is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Its product candidates are prodrugs that are created by modifying the chemical structure of currently marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and metabolism of the parent drug. Its marketed product and each of its product candidates are orally available, patented molecules that address potential markets with clear unmet medical needs. Its marketed product is approved in the United States, where it is known as Horizant Extended-Release Tablets, and in Japan, where it is known as Regnite Extended-Release Tablets. Horizant has been approved by the U.S. Food and Drug Administration, or FDA, for the treatment of moderate-to-severe primary restless legs syndrome, or RLS, in adults and for the management of postherpetic neuralgia, or PHN, in adults. Restless legs syndrome, also known as Willis-Ekbom Disease, is a neurological disorder characterized by an urge to move the legs, usually caused or accompanied by uncomfortable and unpleasant sensations in the legs. PHN is a neuropathic pain syndrome that can follow the healing of an outbreak of herpes zoster, commonly known as shingles. Regnite has been approved by the Japanese Ministry of Health, Labor and Welfare, or MHLW, as a treatment for patients with moderate-to-severe RLS. It is also engaged with third parties for the development of arbaclofen placarbil, or AP, a potential treatment for spasticity in patients with spinal cord injury; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson's disease. With respect to AP, it has decided to terminate further investment in AP as a treatment for spasticity in patients with MS; however, given a previous, successful Phase 2 clinical trial of AP as a potential treatment for spasticity in spinal cord injury patients. XP21279, in the primary analysis of the trial, the improvement with XP21279/carbidopa dosed three times per day was not statistically good than the improvement seen with optimized Sinemet dosed four or five times per day during the double-blind phase of the trial. It has discussed the results of this trial with experts in Parkinson's disease and with regulatory authorities. As a result, it plans to continue development of XP21279 to the extent its resources permit or it enters into collaboration with a third party. The Company faces competition from manufacturers of generic drugs. The Company is subject to regulation by regional, national, state and local agencies, including the Department of Justice, the Federal Trade Commission, the Office of Inspector General of the U.S. Department of Health and Human Services and other regulatory bodies, as well as govern
» More Articles for XNPT

Headlines

Articles On GuruFocus.com
comment on XNPT Mar 15 2013 
comment on XNPT Mar 06 2013 
XenoPort Inc. Reports Operating Results (10-Q) Nov 09 2010 
XenoPort Inc. Reports Operating Results (10-Q) Aug 06 2010 
XenoPort Inc. Reports Operating Results (10-Q) May 10 2010 
Xenoport - A Shaking Ham Hock Feb 07 2010 
XenoPort Inc. Reports Operating Results (10-Q) Aug 06 2009 
XenoPort Reports Second Quarter Financial Results Aug 05 2009 
Weekly Top Insider Buys: Alcoa Inc., ABM Industries Inc., Valhi Inc., XenoPort Inc., and Methode Ele Jul 11 2009 
XenoPort Inc. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
XenoPort to Present New Data Analyses for HORIZANT (gabapentin enacarbil) at the 67th Annual Meeting... Apr 15 2015
XenoPort to Present New Data Analyses for HORIZANT (gabapentin enacarbil) at the 67th Annual Meeting... Apr 15 2015
XENOPORT INC Financials Mar 10 2015
XenoPort to Present at the Cowen and Company 35th Annual Health Care Conference Mar 02 2015
10-K for XenoPort, Inc. Mar 01 2015
XENOPORT INC Files SEC form 10-K, Annual Report Feb 27 2015
XenoPort to Present at the Cowen and Company 35th Annual Health Care Conference Feb 23 2015
Xenoport Inc Earnings Call scheduled for 5:00 pm ET today Feb 19 2015
XENOPORT INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors... Feb 19 2015
XenoPort Reports Fourth Quarter and Year-End 2014 Financial Results Feb 19 2015
Q4 2014 Xenoport Inc Earnings Release - After Market Close Feb 19 2015
XenoPort to Present at the RBC Capital Markets' Global Healthcare Conference Feb 18 2015
XenoPort to Present at the RBC Capital Markets’ Global Healthcare Conference Feb 18 2015
Biotech Stock Roundup: Achillion Impresses with HCV Data, Regeneron 4Q Results Top Estimates -... Feb 11 2015
XenoPort to Release Fourth Quarter and Year-End Financial Results on February 19, 2015 Feb 05 2015
XenoPort to Release Fourth Quarter and Year-End Financial Results on February 19, 2015 Feb 05 2015
XENOPORT INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Feb 03 2015
XenoPort Announces Pricing of $100 Million 2.50% Convertible Senior Notes due 2022 Jan 29 2015
XenoPort Announces Pricing of $100 Million 2.50% Convertible Senior Notes due 2022 Jan 29 2015
XENOPORT INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Jan 28 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK